Projected top future IBD drugs based on expected 2022 revenue

This statistic displays a projection of the top future inflammatory bowel disease drugs based on expected 2022 revenues worldwide. During this time, Janssen's Stelara, a therapy targeting Crohn's disease with expected approval in 2015, is expected to generate 399.5 million U.S. dollars in 2022 revenues. Approximately, 1 to 1.3 million people currently suffer from IBD in the United States, however, the cause of IBD is currently unknown. IBD occurs in the colon and intestine and can also impact other parts of the body.

本统计数据显示了基于全球预期2022年收益预测的前瞻性炎症性肠病药物排名。在此期间，强生公司的Stelara疗法，针对克罗恩病，预计将于2015年获得批准，预计将在2022年产生3.995亿美元的收益。据估计，目前约有100万至130万人在美国患有炎症性肠病，然而，炎症性肠病的病因目前尚不清楚。炎症性肠病发生于结肠和肠道，也可能影响身体的其他部分。